Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Belite Bio, Inc - American Depositary Shares (NQ:BLTE)

173.00 -0.79 (-0.45%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 186,054
Open 172.98
Bid (Size) 172.58 (100)
Ask (Size) 173.01 (100)
Prev. Close 173.79
Today's Range 171.82 - 178.04
52wk Range 64.80 - 200.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease ↗
Belite Bio (NASDAQ:BLTE) said the U.S. Food and Drug Administration has accepted its new drug application for tinlarebant as a treatment for Stargardt disease type 1, granted the application priority... 
Via MarketBeat

Performance

YTD
+8.6%
+8.6%
1 Month
+6.3%
+6.3%
3 Month
+19.9%
+19.9%
6 Month
+4.6%
+4.6%
1 Year
+159.0%
+159.0%

More News

Read More
News headline image
Belite Bio to Participate in Four Upcoming Investor Conferences
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Host Virtual Commercial Day on September 2, 2026
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Full Transcript: Belite Bio Q2 2026 Earnings Call ↗
Via Benzinga
Topics Earnings
News headline image
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Conference Highlights Tinlarebant Data and New Hope for Retinal Diseases ↗
Via MarketBeat
News headline image
Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Eyes Priority FDA Review as Tinlarebant Targets Stargardt Disease ↗
Via MarketBeat
News headline image
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Belite Bio (BLTE) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire

Frequently Asked Questions

Is Belite Bio, Inc - American Depositary Shares publicly traded?
Yes, Belite Bio, Inc - American Depositary Shares is publicly traded.
What exchange does Belite Bio, Inc - American Depositary Shares trade on?
Belite Bio, Inc - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Belite Bio, Inc - American Depositary Shares?
The ticker symbol for Belite Bio, Inc - American Depositary Shares is BLTE on the Nasdaq Stock Market
What is the current price of Belite Bio, Inc - American Depositary Shares?
The current price of Belite Bio, Inc - American Depositary Shares is 173.00
When was Belite Bio, Inc - American Depositary Shares last traded?
The last trade of Belite Bio, Inc - American Depositary Shares was at 09/14/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.